Company Insights

IDYA customer relationships

Explore interactive graphBrowse insights index
IDYA customer relationship map

Ideaya Biosciences: partner-led value creation and where revenue actually comes from

Ideaya Biosciences discovers and advances precision oncology candidates and monetizes primarily through exclusive licensing deals, upfront payments, and staged collaboration revenue tied to R&D performance rather than immediate product sales. The company’s operating model converts early-stage biology into de-risked assets that larger partners will fund and commercialize; that structure produces episodic, high-impact cash inflows (upfronts) and recurring collaboration revenue recognized over the course of development. For investors evaluating Ideaya customer relationships, the partner map is the primary lens on near-term cash, revenue quality, and commercialization optionality. Read more about our coverage at https://nullexposure.com/.

How Ideaya’s partner strategy converts science into finance

Ideaya runs a classic biotech monetization playbook: internal discovery and early clinical development, then exclusive out-licenses and development collaborations that transfer later‑stage risk and commercialization obligations to established pharma companies. That posture creates several company-level operating characteristics investors must track:

  • Contracting posture — partner-centric, license-heavy. Ideaya routinely uses exclusive licenses and collaboration agreements to monetize programs; revenue is driven by contract terms and timing of performance milestones rather than product sales.
  • Revenue concentration — episodic and lumpy. A small number of large license payments can materially change cash balances and reported collaboration revenue in any given quarter.
  • Criticality — partner execution determines commercial outcome. Ideaya’s ability to realize milestones and royalties depends on partners’ clinical and regulatory execution after license handoff.
  • Maturity — pipeline still development-stage. Programs cited in filings and press releases are in clinical or pre-commercial stages; public valuation depends on successful partner development and regulatory approvals.

These are company-level signals grounded in the public record, not speculative commentary. For a practical investor checklist on partner risk and revenue timing, see https://nullexposure.com/.

The partner list, relationship by relationship

Cancer Research UK

Ideaya holds an exclusive in-license from Cancer Research UK and the University of Manchester and is collaborating to clinically evaluate IDE161 in combination with Merck’s KEYTRUDA in endometrial cancer. According to Ideaya’s FY2024 Form 10‑K, the Cancer Research UK / University of Manchester license underpins discovery-stage rights that enabled clinical combination studies. (FY2024 10‑K)

Servier

Servier is a strategic commercial partner for darovasertib—Ideaya received a significant upfront and recognizes collaboration revenue for research services performed under the exclusive license. A PR Newswire release covering Ideaya’s fourth-quarter and full-year 2025 results disclosed a $210.0 million upfront payment from Servier received during 2025, and news reports noted collaboration revenue recognized through December 31, 2025 tied to Servier research and development performance obligations. (Q4 2025 financial results; PR Newswire and related coverage)

Les Laboratoires Servier

Ideaya’s SEC filing and subsequent coverage list an exclusive license agreement with Les Laboratoires Servier for development and commercialization of darovasertib outside the United States, positioning Servier as the outside‑U.S. commercialization partner. TradingView’s coverage of Ideaya’s 10‑K highlights this arrangement among the company’s key initiatives. (FY2026 10‑K coverage via TradingView)

Hengrui Pharma

Ideaya licensed IDE849 to Hengrui; the transaction included a material upfront payment and shifted development responsibilities for that program. Company reporting and press coverage indicate a $75.0 million upfront received under the IDE849 license, and Ideaya reported corresponding increases in development spend to support these programs. (Q4 2025 financial results; PR Newswire and associated news)

Pfizer

Ideaya lists an established collaboration with Pfizer to support clinical development and commercialization efforts, indicating Pfizer’s role as a development partner for select programs. TradingView’s coverage of the company’s 10‑K enumerated Pfizer among the external collaborators helping advance Ideaya’s clinical programs. (FY2026 10‑K coverage via TradingView)

Gilead

Gilead is reported as an established collaborator that supports Ideaya’s clinical development and commercialization efforts, reinforcing the company’s strategy of pairing assets with major biopharma partners. TradingView summarized Gilead alongside Pfizer and Servier in its reporting on Ideaya’s corporate collaborations. (FY2026 10‑K coverage via TradingView)

GlaxoSmithKline

GlaxoSmithKline terminated a prior collaboration and returned two clinical programs—Werner Helicase (IDE275) and Pol Theta (IDE705)—to Ideaya, per December 2025 notices; this development restores asset ownership to Ideaya and alters the company’s program portfolio. SimplyWallSt reported that GSK’s December 2025 notification will return those programs to Ideaya within approximately 90 days. (December 2025 reporting via SimplyWallSt)

What these relationships mean for cash flow and valuation

The partner map explains Ideaya’s cash and revenue profile more directly than pipeline milestones alone. Upfront payments and license proceeds are the company’s principal near-term sources of cash, while revenue is frequently recognized over time as research services are delivered under collaboration contracts. The combination of large upfronts and ongoing R&D expense yields the following investor implications:

  • Liquidity spikes versus recurring revenue. Upfronts create cash runway events; sustainable revenue requires milestone attainment and future royalties.
  • Concentration risk. A handful of large partners will account for material portions of collaboration receipts in any reporting period, introducing binary outcomes tied to partner execution.
  • Operational leverage to partners. Ideaya transfers late-stage development and commercialization risk to licensees, which accelerates value realization if partners execute but reduces retained upside if program economics favor the licensee.

Financially, Ideaya reported trailing twelve‑month revenue of $218.7 million and negative gross profit and EBITDA, reflecting the R&D‑intensive model and the timing of collaboration accounting. Investors should treat reported revenue as contract‑dependent and scrutinize recognition schedules and milestone earnouts when modeling future cash flows.

For a consolidated view of partner-level risk and timeline exposure, visit https://nullexposure.com/ and see our partner risk matrix.

Investment takeaways and next steps

Ideaya’s business is partner-enabled value creation: discovery and early clinical development within Ideaya, followed by monetization through exclusive licenses and collaborations that produce episodic cash inflows. That model creates high upside tied to successful partner execution and significant binary exposure if one or two licensees control program outcomes. The return of GSK programs increases Ideaya’s retained asset base but also adds development obligations.

Actionable next steps for investors:

  • Monitor milestone schedules and revenue recognition language in Ideaya’s quarterly filings to time potential cash inflows.
  • Track partner clinical progress (Servier for darovasertib; Hengrui for IDE849) as the primary drivers of near-term valuation moves.
  • Review Ideaya’s cash runway after upfronts and R&D spend to assess dilution risk and financing cadence.

To follow updates and get a partner-centric view of biotech risk, check https://nullexposure.com/ for continuing coverage and model-friendly summaries.